NEW YORK (GenomeWeb) – PhoreMost announced today that it has formed a collaboration with The Wistar Institute to identify novel drug targets in cancer, aging, and immune disorders.
Under the terms of the arrangement, Wistar scientists will develop high-throughput phenotypic assays for currently undruggable disease targets. PhoreMost will use its Siteseeker live-cell phenotypic screening platform to find points of possible therapeutic intervention for these targets, then develop small molecules against them.
Wistar will also provide specialist disease biology knowledge and drug mode-of-action studies on a project-by-project basis to support PhoreMost's drug-discovery efforts.
Additional terms were not disclosed.